Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Psychische Erkrankungen und Diabetes mellitus

verfasst von: Heidemarie Abrahamian, Alexandra Kautzky-Willer, Angelika Rießland-Seifert, Peter Fasching, Christoph Ebenbichler, Peter Hofmann, Hermann Toplak

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Diabetes mellitus ist häufig mit psychischen Erkrankungen assoziiert. Depressive Störungen kommen bei diabetischen PatientInnen doppelt so häufig vor wie in der nicht-diabetischen Population. Andere psychische Erkrankungen, die gehäuft mit Prädiabetes und Diabetes mellitus vorkommen, sind kognitive Dysfunktionen bis zur Demenz, auffälliges Essverhalten, Angststörungen, Schizophrenie, bipolare Störungen und Borderline -Persönlichkeitsstörungen. Die ungünstigen Auswirkungen dieser Koinzidenz auf den Stoffwechsel sind nachhaltig und manifestieren als schlechtere metabolische Kontrolle und vermehrte mikro- und makroangiopathische Komplikationen. Ziel dieses Positionspapieres ist sowohl die Sensibilisierung aller involvierten medizinischen FachkollegInnen sowie sonstiger mit dem Thema befasster Berufsgruppen und Organisationen als auch die Intensivierung der komplexen therapeutischen Interventionen bei PatientInnen. Positive Auswirkungen wären die Verringerung der Inzidenz von Diabetes mellitus bei PatientInnen mit psychischen Erkrankungen, die konsekutive Reduktion von Spätfolgen, insbesondere der kardiovaskulären Morbidität und Mortalität sowie eine verbesserte Lebensqualität der Betroffenen.
Literatur
1.
Zurück zum Zitat De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24. CrossRefPubMed De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24. CrossRefPubMed
3.
Zurück zum Zitat American Diabetes Association. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care and immunization. Sec. 4. in Standards of Medical Care in Diabetes – 2015. Diabetes Care. 2015;38 (Suppl 1):S20–30. CrossRef American Diabetes Association. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care and immunization. Sec. 4. in Standards of Medical Care in Diabetes – 2015. Diabetes Care. 2015;38 (Suppl 1):S20–30. CrossRef
4.
Zurück zum Zitat De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58. CrossRefPubMed De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58. CrossRefPubMed
5.
Zurück zum Zitat Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis. Br J Psychiatry. 2008;192(6):406–11. CrossRefPubMed Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis. Br J Psychiatry. 2008;192(6):406–11. CrossRefPubMed
6.
Zurück zum Zitat Katon W, Ming-Yu F, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008;23(10):1571–5. CrossRefPubMedPubMedCentral Katon W, Ming-Yu F, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008;23(10):1571–5. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Sullivan MD, O’Connor P, Feeney P, et al. Depression predicts all-cause mortality. Epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care. 2012;35:1708–15. CrossRefPubMedPubMedCentral Sullivan MD, O’Connor P, Feeney P, et al. Depression predicts all-cause mortality. Epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care. 2012;35:1708–15. CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes. Diabetes Care. 2001;24:1069–78. CrossRefPubMed Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes. Diabetes Care. 2001;24:1069–78. CrossRefPubMed
9.
Zurück zum Zitat Abrahamian H, Hofmann P, Prager R, Toplak H. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261–6. CrossRefPubMedPubMedCentral Abrahamian H, Hofmann P, Prager R, Toplak H. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261–6. CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837–45. CrossRefPubMed Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837–45. CrossRefPubMed
11.
Zurück zum Zitat Ali S, Stone A, Peters L, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165–73. CrossRefPubMed Ali S, Stone A, Peters L, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165–73. CrossRefPubMed
12.
Zurück zum Zitat Nicolucci A, Kovacs Burns K, Holt RI, et al. Diabetes attitudes, wishes and Needs second study (DAWN2): crossnational benchmarking of diabetes- related psychosocial outcomes for people with diabetes. Diabet med. 2013;30(7):767–77. CrossRefPubMed Nicolucci A, Kovacs Burns K, Holt RI, et al. Diabetes attitudes, wishes and Needs second study (DAWN2): crossnational benchmarking of diabetes- related psychosocial outcomes for people with diabetes. Diabet med. 2013;30(7):767–77. CrossRefPubMed
13.
Zurück zum Zitat Gonzalez JS, Delahanty LM, Safren SA, Meigs JB, Grant RW. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. Diabetologia. 2008;51(10):1822–5. CrossRefPubMedPubMedCentral Gonzalez JS, Delahanty LM, Safren SA, Meigs JB, Grant RW. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. Diabetologia. 2008;51(10):1822–5. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Hautzinger M, Keller F, Kühner C. Beck Depressions-Inventar (BDI-II). Revision. Frankfurt a. M.: Harcourt Test Services; 2006. Hautzinger M, Keller F, Kühner C. Beck Depressions-Inventar (BDI-II). Revision. Frankfurt a. M.: Harcourt Test Services; 2006.
16.
Zurück zum Zitat Herrmann-Lingen C, Buss U, Snaith RPHADS-D. Hospital Anxiety and Depression Scale – Deutsche Version. 3. aktualisierte Aufl. Bern: Huber; 2011. Herrmann-Lingen C, Buss U, Snaith RPHADS-D. Hospital Anxiety and Depression Scale – Deutsche Version. 3. aktualisierte Aufl. Bern: Huber; 2011.
18.
Zurück zum Zitat Correll CU, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36. Correll CU, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36.
19.
Zurück zum Zitat Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26(2):153–61. CrossRefPubMed Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26(2):153–61. CrossRefPubMed
20.
Zurück zum Zitat Ludman E, Katon W, Russo J, et al. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28:475–81. CrossRefPubMed Ludman E, Katon W, Russo J, et al. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28:475–81. CrossRefPubMed
22.
Zurück zum Zitat Markowitz JT, Butler DA, Vokening LK, et al. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33:495–500. CrossRefPubMedPubMedCentral Markowitz JT, Butler DA, Vokening LK, et al. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33:495–500. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kahl KG, Greggersen W, Schweiger U, et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013;263(3):205–13. CrossRefPubMed Kahl KG, Greggersen W, Schweiger U, et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013;263(3):205–13. CrossRefPubMed
24.
Zurück zum Zitat Mai Qu, CDÀrcy H, Sanfilippo FM, Emery JD, Preen DB. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med. 2011;9:118. CrossRefPubMedPubMedCentral Mai Qu, CDÀrcy H, Sanfilippo FM, Emery JD, Preen DB. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med. 2011;9:118. CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53. CrossRefPubMed Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53. CrossRefPubMed
26.
Zurück zum Zitat Jones BJ, Gallagher BJ, Moss DM, McFalls JA. Obstetrical complications, social class and type of schizophrenia. Clin Schizophr Relat Psychoses. 2011;5(1):33–9. CrossRefPubMed Jones BJ, Gallagher BJ, Moss DM, McFalls JA. Obstetrical complications, social class and type of schizophrenia. Clin Schizophr Relat Psychoses. 2011;5(1):33–9. CrossRefPubMed
27.
Zurück zum Zitat Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11. CrossRefPubMed Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11. CrossRefPubMed
28.
Zurück zum Zitat Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes – systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9. CrossRefPubMed Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes – systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9. CrossRefPubMed
30.
Zurück zum Zitat Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842–52. CrossRefPubMed Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842–52. CrossRefPubMed
31.
32.
Zurück zum Zitat Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurol. 2011;10(11):969–77. CrossRefPubMedPubMedCentral Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurol. 2011;10(11):969–77. CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ress C, Tschoner A, Kaser S, Ebenbichler C. Psychopharmaka und diabetes. Wien Med Wochenschr. 2011;161(21–22):531–42. CrossRefPubMed Ress C, Tschoner A, Kaser S, Ebenbichler C. Psychopharmaka und diabetes. Wien Med Wochenschr. 2011;161(21–22):531–42. CrossRefPubMed
34.
Zurück zum Zitat Bushe CJ, Leonard BE. Blood glucose and schizophrenia – a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68(11):1682–90. CrossRefPubMed Bushe CJ, Leonard BE. Blood glucose and schizophrenia – a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68(11):1682–90. CrossRefPubMed
35.
Zurück zum Zitat Prisciandaro JJ, Gebregziabher M, Grubaugh AL, Gilbert GE, Echols C, Egede LE. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes. Diabetes Technol Ther. 2011;13(1):73–8. CrossRefPubMedPubMedCentral Prisciandaro JJ, Gebregziabher M, Grubaugh AL, Gilbert GE, Echols C, Egede LE. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes. Diabetes Technol Ther. 2011;13(1):73–8. CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry. 2004;184:58–62. CrossRefPubMed Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry. 2004;184:58–62. CrossRefPubMed
37.
38.
Zurück zum Zitat Delamater AM, Jacobson AM, Anderson B, Cox D, Fisher L, et al. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7. CrossRef Delamater AM, Jacobson AM, Anderson B, Cox D, Fisher L, et al. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7. CrossRef
39.
Zurück zum Zitat Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes. Diabetes Care. 2001;24:561–8. CrossRefPubMed Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes. Diabetes Care. 2001;24:561–8. CrossRefPubMed
41.
42.
Zurück zum Zitat Von Mach MA, Gauer M, Meyer S, Omogbehin B, Schinzel H. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44(2):51–4. CrossRef Von Mach MA, Gauer M, Meyer S, Omogbehin B, Schinzel H. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44(2):51–4. CrossRef
43.
Zurück zum Zitat Lustmann PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behaviour therapy for depression in type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med. 1998;129(8):613–21. CrossRef Lustmann PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behaviour therapy for depression in type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med. 1998;129(8):613–21. CrossRef
44.
Zurück zum Zitat Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22. CrossRefPubMedPubMedCentral Bogner HR, Morales KH, de Vries HF, Cappola AR. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22. CrossRefPubMedPubMedCentral
45.
46.
Zurück zum Zitat Georgiades A, Zucker N, Friedman KE, Mosunic CJ, Applegate K, et al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med. 2007;69(3):235–41. CrossRefPubMed Georgiades A, Zucker N, Friedman KE, Mosunic CJ, Applegate K, et al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med. 2007;69(3):235–41. CrossRefPubMed
47.
Zurück zum Zitat Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51(1):5–15. CrossRefPubMed Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51(1):5–15. CrossRefPubMed
48.
Zurück zum Zitat Wang MY, Tsai PS, Chou KR, Chen CM. A systematic review of the efficacy of non-pharmacological treatments for depression on glycemic control in type 2 diabetics. J Clin Nurs. 2008;17(19):2524–30. CrossRefPubMed Wang MY, Tsai PS, Chou KR, Chen CM. A systematic review of the efficacy of non-pharmacological treatments for depression on glycemic control in type 2 diabetics. J Clin Nurs. 2008;17(19):2524–30. CrossRefPubMed
49.
Zurück zum Zitat Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry. 2007;46:1123–31. CrossRef Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry. 2007;46:1123–31. CrossRef
51.
Zurück zum Zitat Correll C, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36. Correll C, Detraux J, Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World. Psychiatry. 2015;14:119–36.
Metadaten
Titel
Psychische Erkrankungen und Diabetes mellitus
verfasst von
Heidemarie Abrahamian
Alexandra Kautzky-Willer
Angelika Rießland-Seifert
Peter Fasching
Christoph Ebenbichler
Peter Hofmann
Hermann Toplak
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0939-8

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe

leitlinien für die praxis

Insulintherapie bei Diabetes mellitus